Precision Bio-Conjugation for Enhanced Enzyme Stability and Next-Generation Biopharmaceuticals. Traditional chemical PEGylation often suffers from low selectivity and the use of harsh reagents that can denature sensitive proteins. CD Biosynsis offers professional Enzymatic Site-Specific PEGylation Services, leveraging the extraordinary selectivity of nature’s own catalysts—such as transglutaminases, glycosyltransferases, and sortases—to attach PEG chains with surgical precision. This chemoenzymatic approach ensures maximum bioactivity retention, superior homogeneity, and enhanced stability for both industrial enzymes and therapeutic proteins.
Get a Technical QuoteOur platform utilizes enzyme-mediated labeling to create high-performance "Biobetters" and robust industrial biocatalysts. By working under mild aqueous conditions, we preserve the native state of complex proteins while achieving absolute site-specificity.
| Service Tier | Technical Focus | Primary Application | Industrial Value |
|---|---|---|---|
| Industrial Biocatalyst Upgrade | Computer-aided design + Enzymatic coupling | PETase Plastic Degradation | 3.5x activity boost & Tm increase |
| Chemoenzymatic Glyco-Tagging | Glycosyltransferase-mediated PEG | Native Proteins & Biosimilars | Optimized PK/PD & Reduced immunogenicity |
| Therapeutic Cytokine Tuning | Site-specific IL-2 modification | Autoimmune & Immunotherapy | Sustained activation of Tregs |
| Enzyme Subunit Crosslinking | Precision PEG-crosslinking | Anti-tumor enzymes (e.g. L-asparaginase) | Extended half-life & uniform ADCs |
1. Structural In Silico Design
2. Recognition Tag Engineering
3. Enzymatic Conjugation
4. Validation & Bioassays
Mapping protein surfaces to locate recognition motifs (Q-tags, G-tags, or Sortase motifs) for site-specific modification.
Formal project proposal and Mutual NDA signing.
If necessary, introducing peptide sequences via recombinant DNA technology to facilitate enzymatic recognition.
Screening for the most efficient catalyst from our proprietary enzyme library.
Executing PEGylation under mild, aqueous conditions (neutral pH) using high-purity transferases or ligases.
Advanced purification using TFF or affinity chromatography to remove the conjugating enzyme.
Verifying homogeneity via SEC and LC-MS, followed by comprehensive assessment of Tm and kinetic parameters (Km, Vmax).
Final delivery of purified conjugates and a detailed physicochemical characterization report.
To deliver world-class results, our technical team continuously monitors and benchmarks our enzymatic protocols against landmark research.
Industrial PET hydrolases often suffer from poor stability. By utilizing computer-aided enzymatic PEGylation, technical benchmarks increased PETase thermal stability by 3.88°C and boosted degradation rates by 3.5-fold at 30°C. This provides a scalable solution for biological plastic waste processing.
(Reference: ACS Applied Materials & Interfaces, 2024)
Native proteins can be upgraded using glycosyltransferases to attach precise glycan/PEG tags. This strategy significantly enhances PK/PD properties while lowering immunogenicity compared to random chemical methods, allowing for the rapid development of superior biosimilars.
(Reference: Nature Biomedical Engineering, 2024)
Interleukin-2 is critical for treating autoimmune diseases. Enzymatic site-specific PEGylation of IL-2 resulted in sustained activation of regulatory T cells (Tregs) and vastly improved in vivo stability, offering new potential for transplant rejection therapies.
(Reference: Nature Biomedical Engineering, 2021)
For anti-cancer enzyme treatments, subunit stability is paramount. Enzymatic PEG-crosslinking creates a uniform, stable conjugate that bypasses hemodynamic barriers more effectively, extending circulatory time while reducing side effects.
(Reference: bioRxiv / Enzyme Subunit Crosslinking, 2018)
Ready to upgrade your biocatalyst or therapeutic protein?
Contact Us1. How does enzymatic PEGylation compare to traditional chemical methods?
Chemical methods (like NHS-ester coupling) target multiple lysines, creating a heterogeneous mixture. Enzymatic methods use specific catalysts to recognize only one or two target spots, ensuring batch-to-batch identity.
2. Does my protein require a specific "tag" for this service?
Some proteins contain native sequences recognized by Transglutaminases. If not, we can easily add a short (5-6 amino acid) peptide tag to the N- or C-terminus via our recombinant expression services.
3. Is this technology scalable for industrial-scale manufacturing?
Yes. Enzymatic reactions are highly efficient and can be performed in standard reactors. We optimize enzyme-to-substrate ratios to make the process cost-effective for large-scale production.
4. What types of enzymes do you use for conjugation?
We maintain a proprietary library including Transglutaminases, Sortases, Glycosyltransferases, and Laccases to select the best catalyst for your specific protein chassis.
5. How do you remove the conjugating enzyme from the final product?
We utilize specialized purification techniques, such as affinity chromatography or Tangential Flow Filtration (TFF), to completely remove the enzyme from the final PEGylated conjugate.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.